Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective
ESC 2017 - Barcelona3' education - Aug. 28, 2017
ESC 2017 A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.
This 3-minute education provides a summary of just presented scientific data, recorded during the ESC 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
Robert Giugliano, MD - cardiologist, Brigham and Women's Hospital (BWH), Boston, MA, USA
Dr. Robert P. Giugliano is a cardiovascular medicine specialist at BWH and an associate professor of medicine at Harvard Medical School. In addition, he is a senior investigator of BWH’s Thrombolysis in Myocardial Infarction (TIMI) Study Group.
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this 3-minute education.